Didier Landais is appointed 4P-Pharma's CEO to lead the company into a new chapter of its development
5.9.2023 11:30:00 EEST | Business Wire | Press release
4P-Pharma, a pioneering biotechnology company based in Lille and specializing in drug regeneration, is thrilled to achieve a significant milestone in its history. During the latest strategic board meeting, the appointment of Didier Landais as the new CEO of 4P-Pharma was confirmed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905514097/en/
DIDIER LANDAIS CEO - 4P-PHARMA
Founded in 2014 by Revital Rattenbach, 4P-Pharma is entering a new era of its development. On September 1st, 2023, Didier Landais succeeds Revital Rattenbach as CEO of 4P-Pharma. She now holds the position of Executive Chairwoman.
With over 30 years of international experience in the pharma/biotech industry, Didier Landais stands out as an executive leader. His career has been marked by accomplishments in key areas such as research and development, strategy, and business development.
His extensive international experience and proven leadership position Didier Landais as the ideal choice for this strategic function. His past achievements attest to his exceptional ability to guide our teams towards excellence, turning ambitious visions into tangible results. Together, the new executive will combine forces to expedite the company's development."
"We stand on the brink of a pivotal period for 4P-Pharma. The appointment of Didier reinforces our commitment to innovation and growth. His passion for scientific research, coupled with his profound market understanding, will propel forward our mission to transform how we approach health and well-being, driving dynamics of success." stated Revital Rattenbach, 4P-Pharma’s Executive Chairwoman
A strong expertise both in France and internationally, to accelerate the development of 4P-Pharma.
Didier Landais holds a Ph.D. in Molecular and Cellular Biology from the University Louis Pasteur (Strasbourg), as well as an Executive MBA from ESSEC (Paris). He started his career as a researcher and oncology project leader at the Gene Therapy Division of RPR-Gencell (Sanofi) before assuming the role of Director of Business Development and General Manager of Cell Therapy, overseeing the international development of a cancer vaccine at IDM Pharma. He has also held positions including Director of Development at Biotecnol and Chief Business Officer at Genome Profiling. Under his leadership as Global Head of Licensing, Servier concluded several notable agreements, including with Celsius, Oncodesign, and Seal Rock. More recently, he served as COO and CBO at Labgenius Ltd in London."
"Joining 4P-Pharma is a significant step for me. We are developing high-potential molecules that truly transform patients' lives. With the support of Revital and our dedicated teams, I am confident that we will reach new horizons and push the boundaries of innovation even further." expressed Didier Landais, 4P-Pharma’s CEO.
As CEO, Didier Landais holds the responsibility for the company's overall strategy in terms of science, partnerships, and external growth. Revital Rattenbach, now 4P-Pharma’s Executive Chairwoman, remains actively involved in financial consolidation and strategic directions, ensuring the continuity of the company's founding vision.
4P-Pharma remains deeply committed to its partners, investors, and its mission to provide innovative solutions to global health challenges."
ABOUT 4P-PHARMA
4P-Pharma is a clinical stage biotech company, pioneering in drug regeneration, founded in Lille in 2014. We focus on untreated serious diseases with high unmet medical needs, aiming to rapidly deliver effective, regenerated, first-in-class therapies. The company has developed a proprietary development engine to address the main pain points of traditional drug development: time, costs, and predictability to deliver optimized risk adjusted returns. We leverage assets with a short time to market, strong IP position, and regulatory opportunities (emergency use or conditional marketing authorizations) in blue-ocean markets.
Website: https://4p-pharma.com/fr
LinkedIn: https://fr.linkedin.com/company/4p-pharma
Twitter: https://twitter.com/4p_pharma
The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905514097/en/
Contact information
Press
Najette Chaib – nchaib@beyondcom.fr 06 18 38 11 14
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NelsonHall Recognizes LTM as a Leader in GenAI & Process Automation for Banking4.3.2026 14:45:00 EET | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as a Leader in the ‘Overall’ market segment in the NelsonHall NEAT Evaluation for GenAI & Process Automation in Banking 2025. In the NEAT framework, Leaders are vendors that demonstrate high capability relative to peers in delivering immediate client benefit while also meeting future client requirements. The recognition positions LTM among the top-performing vendors evaluated for their ability to deliver both immediate business impact and long-term innovation capability in GenAI and process automation services for the banking sector. The evaluation highlights LTM’s depth of experience in financial services, which accounts for a large portion of its overall revenues, and its focused investments in GenAI, agentic AI, and process automation capabilities delivered through its BlueVerse™ platform. LTM has digital agents dedicated to manage GenAI and process automation services, supporting banking cl
Americhem Expands Aircraft Interior Portfolio with PFAS-Free Thermoplastic Platform Meeting 55/55 OSU, Low Smoke, and Low Toxicity Requirements4.3.2026 14:00:00 EET | Press release
Americhem is expanding its aircraft interior materials portfolio with ColorFast® SFT5500, a PFAS-free high-performance thermoplastic engineered to meet FAA 14 CFR 25.853, Appendix F, Part IV, 55/55 OSU heat release requirements while delivering low smoke and low toxicity characteristics for aircraft interior applications. PFAS-free thermoplastic systems capable of achieving 55/55 OSU performance while maintaining low smoke and low toxicity characteristics remain limited in the aerospace market. ColorFast® SFT5500 addresses this need with demonstrated 55/55 OSU heat release performance, low smoke emission characteristics, and low flaming-mode toxicity performance in a high-performance thermoplastic platform designed specifically for injection-molded interior components. Aircraft interior thermoplastics must meet stringent fire standards while maintaining durability, thermal stability, and process consistency. As legacy fluorinated material systems face increasing regulatory scrutiny, ma
NETSCOUT Reveals Qualitative Shifts in DDoS Attack Sophistication, Infrastructure Capacity, and Threat Actor Capabilities4.3.2026 13:05:00 EET | Press release
NETSCOUT® SYSTEMS, INC. (NASDAQ: NTCT), today released its second half of the year 2025 Distributed Denial-of-Service (DDoS) Threat Intelligence Report, revealing sophisticated attacker collaboration, resilient botnets, and compromised IoT infrastructure that drove more than eight million DDoS attacks worldwide – some as large as 30 terabits per second (Tbps) – marking a new era of hyper-scale, coordinated threat activity that continues to outpace global takedown efforts. Meanwhile, the accelerating growth of DDoS-for-hire services is empowering a broader range of threat actors, intensifying operational risk to digitally connected organizations and enterprises. Implications for security professionals extend far beyond volumetric concerns and include reconnaissance and adaptive evasion which challenge traditional defense paradigms. Organizations must match adversarial innovation with intelligent, autonomous defenses, or risk operational disruption at levels previously considered theoret
WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform Globally4.3.2026 13:00:00 EET | Press release
WHOOP, the human performance company, today announced plans to add more than 600 new roles across Software, Research & Design, Hardware, Product, and Marketing as the company continues to scale globally. The hiring expansion reflects a clear strategic priority: bolstering a team that will define the future of human performance and health technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304866977/en/ WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform Globally “Right now, companies are debating whether to hire more people or just invest in AI,” said Will Ahmed, Founder and CEO of WHOOP. “We are doing both. We are doubling down on exceptional talent and doubling down on world-class AI tools because the combination is what wins. Health monitoring is becoming one of the most important platforms in the world, and WHOOP intends to own the category.” The hiring expansion
Radian Arc, VNPT and Blacknut Launch GPU Infrastructure in Vietnam, Enabling Cloud Gaming and AI Services4.3.2026 12:00:00 EET | Press release
Radian Arc, part of inferX, Submer’s AI cloud and GPU infrastructure platform has partnered with VNPT, and COMIT, to launch Cloud Gaming powered by Radian Arc’s GPU Edge Platform and Blacknut’s global cloud gaming service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303986657/en/ Radian Arc, VNPT and Blacknut Launch GPU infrastructure in Vietnam, enabling cloud gaming and AI services This deployment expands Radian Arc and Blacknut’s global cloud gaming partnership into the Vietnam market with VNPT and lays the foundation for future AI-native services and sovereign infrastructure together with COMIT. The deployment represents a commercial proof point of Radian Arc’s carrier-embedded GPU model, combining monetizable consumer services today with scalable AI infrastructure that can support sovereign AI workloads. “With VNPT’s market reach and Blacknut’s premium gaming catalog we’re bringing the next generation of interacti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom